During a recent OncLive Peer Exchange® roundtable, experts discussed novel targeted agents for cholangiocarcinomas progressing through the pipeline, such as infigratinib and pemigatinib, which are selective pan-inhibitors of FGFR fusions/translocations being evaluated in phase III trials.
Dr. Wojciech Jurczak presents first disclosure results from the EPCORE DLBCL-3 trial, demonstrating that fixed-duration subcutaneous epcoritamab monotherapy achieves high response rates with a manageable…
Sara M. Tolaney, MD, MPH, discusses the value of incorporating ctDNA monitoring of ESR1 mutations into routine management for HR-positive breast cancer.
Nerea Lopetegui-Lia, MD, discusses fertility preservation options for patients with TNBC and considerations for managing treatment-related toxicities.
Paolo Tarantino, MD, discusses adjuvant strategies, trial data, and risk stratification shaping HER2+ breast cancer care.
Dr. Rugo has led key breast cancer therapy trials and exudes a passion for serving patients
China’s NMPA has accepted an sNDA for review, seeking the approval of repotrectinib for advanced solid tumors harboring NTRK fusions.
The combination of sacituzumab govitecan and pembrolizumab improved PFS vs pembrolizumab plus chemotherapy in PD-L1–positive mTNBC.
Frontline T-DXd plus pertuzumab led to statistically significant and clinically meaningful PFS improvements vs THP in HER2+ metastatic breast cancer.
Nataliya Mar, MD, discusses clinical considerations when selecting between the wide range of androgen receptor pathway inhibitors in prostate cancer.
Fawzi F Abu Rous, MD, discusses ongoing efforts to address unmet needs in the management of squamous cell carcinoma of the lung.
